WeVote
Log In

Bill

MY

Bill

SB 112

Revise laws related to state purchase of opioid antagonists

2025 Regular Session Introduced by Mike Yakawich

Montana bill would revise state opioid antagonist purchasing laws to potentially expand access to naloxone for overdose emergencies.

(H) Died in Standing Committee
#rulemaking #alcohol #publiccontracts
0
WeVote Research Nonpartisan
Bill Summary · SB 112

Legislative bill overview

SB 112 would revise Montana's laws governing state procurement and distribution of opioid antagonists (primarily naloxone/Narcan), which reverse opioid overdoses. The bill appears designed to streamline how state agencies purchase and potentially distribute these life-saving medications, though specific provisions are not detailed in the available action history.

Why is this important

Opioid overdose deaths remain a significant public health crisis. Expanding access to opioid antagonists through state purchase programs can increase availability in communities, emergency services, and public spaces. This directly affects overdose survival rates and reflects evolving public health policy around harm reduction and emergency preparedness.

Potential points of contention

  • Cost and budget allocation: Expanding state purchase of opioid antagonists requires dedicated funding, which may compete with other healthcare priorities during budget constraints
  • Distribution method concerns: Disagreement may exist over whether antagonists should be distributed widely (pharmacies, public spaces, schools) versus restricted to medical professionals, with debates around liability and effectiveness
  • Addiction treatment vs. emergency response: Some stakeholders may argue resources should prioritize long-term addiction treatment rather than emergency response measures

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.